566 68Gallium-HBED-CC-PSMA PET compared to conventional bone scintigraphy for evaluation of bone metastases in prostate cancer patients

Eiber, Matthias; Pyka, Thomas; Okamoto, Soichiro; Rauscher, Isabel; Dahlbender, M.; Tauber, Robert; Retz, Margitta; Gschwend, J.; Schwaiger, Markus; Maurer, Tobias

doi:10.1016/s1569-9056(16)60568-7

Cited by 8 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 12 68 Ga-PSMA PET/CT is superior to standard routine imaging in detecting lymph node metastasis, 13 and bony metastases. 14 This explains our findings where the introduction of the 68 Ga-PSMA PET/CT scan resulted in the decreased use of CT and bone scans. Interestingly, there has been an associated decline in the use of PLND as PSMA scans have been adopted.…”

Section: Discussionmentioning

confidence: 62%

Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016

Carlaw

Woo

2017

Prostate International

View full text Add to dashboard Cite

BackgroundApproaches to prostate cancer (PCa) diagnosis and treatment have evolved significantly over past decades. There has been an increasing focus on minimizing overdiagnosis and overtreatment of clinically insignificant PCa. The objective of this study was to evaluate the changes in the diagnostic approach and initial treatment strategy that has evolved over time in an Australian urological private practice.Materials and methodsMen with newly diagnosed PCa were identified from the private practice electronic and paper medical records from 2005 to 2016 and data was consolidated into six groups of 2-year intervals. Diagnostic strategy was analyzed with particular reference to the use of multiparametric magnetic resonance imaging (mpMRI) scan and 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) scans. National Comprehensive Cancer Network risk group stratification was correlated with initial treatment strategy and compared over time.ResultsChart review identified 839 men who had a mean age of 65.8 years. In 2011–2012, prebiopsy mpMRI scan was introduced. Its uptake correlated with a decrease in numbers of men diagnosed with low risk cancer (r = -0.80, P = 0.04) and an increase in numbers of men diagnosed with high-risk cancer (r = 0.90, P = 0.01). The use of 68Ga-PSMA PET/CT was associated with decreasing use of CT and bone scans performed. Open radical prostatectomy had a declining trend particularly when robotic surgery (robotic assisted radical prostatectomy (RARP)) was introduced. Pelvic lymph node dissections performed progressively decreased. An increased use of luteinizing hormone receptor hormone (LHRH) antagonists was seen in favor of LHRH agonists. Whilst use of high dose rate brachytherapy declined, there was an increased use of low dose rate brachytherapy.ConclusionPrebiopsy mpMRI has been associated with an increased proportion of newly diagnosed men having clinically significant PCa. Over time, 68Ga-PSMA PET/CT scans, robotic assisted radical prostatectomy (RARP) and LHRH antagonists have increased in use, whilst CT and bone scans, and pelvic lymph node dissections have decreased.

show abstract

Section: Discussionmentioning

confidence: 62%

Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016

Carlaw

Woo

2017

Prostate International

View full text Add to dashboard Cite

show abstract

“…Thus, 68 Ga-PSMA-11 PET/MRI scan could be used for the detection of locally recurrent PCa. This result exceeds the sensitivity of other available non-PSMA PET tracers in the recurrence setting or for conventional imaging ( 29 , 30 ).…”

Section: Psma-pet Tracersmentioning

confidence: 75%

“…In the setting of metastatic disease, Pyka et al compared standard plain 99m Tc bone scintigraphy and 68 Ga-PSMA-11 PET/CT scan for the detection of bone metastases in 126 patients with PCa ( 30 ). 68 Ga-PSMA-11 PET/CT was shown to perform with a significantly higher diagnostic accuracy than bone scintigraphy for the assessment of overall bone involvement (PET/CT and scintigraphy sensitivity were 99–100% and 87–89%, respectively; specificity 88.2–100% and 61–96%, respectively).…”

Section: Psma-pet Tracersmentioning

confidence: 99%

Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents

Czarniecki

Mena

Lindenberg

et al. 2018

Transl. Androl. Urol

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) is an emerging prostate cancer imaging method, which has been reported to have a higher sensitivity and specificity than the currently approved PET imaging agents. Multiple PSMA ligands are being investigated around the world and applications range from primary tumor characterization, to local staging, biochemical recurrence, metastasis, and image-guided interventions. The most investigated PET tracers are labelled with 68-Gallium or 18-Fluoride and are discussed in this review. Additionally, 99mTc labeled PSMA agents for single photon emission computed tomography (SPECT) imaging are elucidated as an alternative method of PSMA image acquisition.

show abstract

“…As demonstrated in some studies 4 , 39 , PSMA PET/CT can detect lymph nodes that measure less than 5 mm in the short-axis diameter, explaining its better sensitivity for nodal detection than CT or MRI. Regarding systemic spread of PCa to bone, few papers have demonstrated the clear superiority of PSMA PET for detecting bone lesions compared to bone scintigraphy (BS), and that BS did not have significant additional diagnostic value in BCR scenario 27 , 40 , 41 . However, focal bone PSMA uptake alone should not be immediately considered metastasis; moreover, if moderate/mild uptake, which has to be correlated with CT morphology, is noted, it can decrease the possibility of false positives 40 , as a few cases of benign lesions with PSMA uptake have been reported 42 , 43 .…”

Section: Introductionmentioning

confidence: 99%

Clinical perspectives of PSMA PET/MRI for prostate cancer

Barbosa¹,

Queiroz²,

Nunes³

et al. 2018

Clinics

View full text Add to dashboard Cite

Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific antigen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for the clinical assessment of PCa.

show abstract

566 68Gallium-HBED-CC-PSMA PET compared to conventional bone scintigraphy for evaluation of bone metastases in prostate cancer patients

Cited by 8 publications

References 0 publications

Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016

Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016

Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents

Clinical perspectives of PSMA PET/MRI for prostate cancer

Contact Info

Product

Resources

About